Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors

Journal of Medicinal Chemistry

Volumn 53, Issue 13, 2010, Pages 5049-5053

  Hu, Qingzhong ^a   Yin, Lina ^a,b   Jagusch, Carsten ^a,c   Hille, Ulrike E ^a   Hartmann, Rolf W ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b ElexoPharm GmbH   (Germany)

^c Dottikon Exclusive Synthesis AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 BROMOPHENYL) 2 METHYL 1 (PYRIDIN 4 YL)PROPAN 1 OL; 4 [1 (4 BROMOPHENYL) 2 METHYLPROP 1 ENYL]PYRIDINE; 4 [1 (4 BROMOPHENYL)2 METHYLPROP 1 ENYL]PYRIDINE; 4' [2 METHYL 1 (PYRIDIN 4 YL)PROP 1 ENYL]BIPHENYL 3 AMINE; 6 [4 (2 METHYL 1 PYRIDIN 4 YL PROPENYL)PHENYL]NAPHTHALEN 2 OL; ABIRATERONE; ALDOSTERONE SYNTHASE; ANDROGEN; AROMATASE; CYP11B1; CYTOCHROME; CYTOCHROME P450 17; CYTOCHROME P450 3A4; KETOCONAZOLE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; DRUG SAFETY; HUMAN; MALE; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS, HORMONAL; BIPHENYL COMPOUNDS; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; PYRIDINES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STEROID 17-ALPHA-HYDROXYLASE; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 77954326488     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100400a     Document Type: Article

References (37)

1. Huhtaniemi, I.; Nikula, H.; Parvinen, M.; Rannikko, S. Histological and functional changes of the testis tissue during GnRH agonist treatment of prostatic cancer Am. J. Clin. Oncol. 1988, 11, S11-S15
2. Titus, M. A.; Schell, M. J.; Lih, F. B.; Tomer, K. B.; Mohler, J. L. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer Clin. Cancer Res. 2005, 11, 4653-4657
3. Stanbrough, M.; Bubley, G. J.; Ross, K.; Golub, T. R.; Rubin, M. A.; Penning, T. M.; Febbo, P. G.; Balk, S. P. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Res. 2006, 66, 2815-2825
4. Montgomery, R. B.; Mostaghel, E. A.; Vessella, R.; Hess, D. L.; Kalhorn, T. F.; Higano, C. S.; True, L. D.; Nelson, P. S. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Res. 2008, 68, 4447-4454
5. Holzbeierlein, J.; Lal, P.; La Tulippe, E.; Smith, A.; Satagopan, J.; Zhang, L.; Ryan, C.; Smith, S.; Scher, H.; Scardino, P.; Reuter, V.; Gerald, W. L. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance Am. J. Pathol. 2004, 164, 217-227
6. Labrie, F.; Dupont, A.; Belanger, A.; Cusan, L.; Lacourciere, Y.; Monfette, G.; Laberge, J. G.; Emond, J. P.; Fazekas, A. T.; Raynaud, J. P.; Husson, J. M. New hormonal therapy in prostatic carcinoma: combined treatment with LHRH agonist and an antiandrogen Clin. Invest. Med. 1982, 5, 267-275
7. Hara, T.; Miyazaki, J.; Araki, H.; Yamaoka, M.; Kanzaki, N.; Kusaka, M.; Miyamoto, M. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome Cancer Res. 2003, 63, 149-153
8. Zhao, X. Y.; Malloy, P. J.; Krishnan, A. V.; Swami, S.; Navone, N. M.; Peehl, D. M.; Feldman, D. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor Nat. Med. (N. Y., NY, U.S.) 2000, 6, 703-706
9. Reed, A. B.; Parekh, D. J. The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer Curr. Opin. Urol. 2009, 19, 238-242
10. Picard, F.; Schulz, T.; Hartmann, R. W. 5-Phenyl substituted 1-methyl-2-pyridones and 4′-substituted biphenyl-4-carboxylic acids: synthesis and evaluation as inhibitors of steroid-5α-reductase type 1 and 2 Bioorg. Med. Chem. 2002, 10, 437-448
11. Baston, E.; Palusczak, A.; Hartmann, R. W. 6-Substituted 1 H -quinolin-2-ones and 2-methoxy-quinolines: synthesis and evaluation as inhibitors of steroid 5α reductases types 1 and 2 Eur. J. Med. Chem. 2000, 35, 931-940
12. Harris, K. A.; Weinberg, V.; Bok, R. A.; Kakefuda, M.; Small, E. J. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer J. Urol. 2002, 168, 542-545
13. Leonetti, F.; Favia, A.; Rao, A.; Aliano, R.; Paluszcak, A.; Hartmann, R. W.; Carotti, A. Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors J. Med. Chem. 2004, 47, 6792-6803
14. Le Borgne, M.; Marchand, P.; Duflos, M.; Delevoye-Seiller, B.; Piessard-Robert, S.; Le Baut, G.; Hartmann, R. W.; Palzer, M. Synthesis and in vitro evaluation of 3-(1-azolylmethyl)-1 H -indoles and 3-(1-azoly1-1- phenylmethyl)-1 H -indoles as inhibitors of P450 arom Arch. Pharm. (Weinheim, Ger.) 1997, 330, 141-145
15. Gobbi, S.; Cavalli, A.; Rampa, A.; Belluti, F.; Piazzi, L.; Paluszcak, A.; Hartmann, R. W.; Recanatini, M.; Bisi, A. Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme J. Med. Chem. 2006, 49, 4777-4780
16. Castellano, S.; Stefancich, G.; Ragno, R.; Schewe, K.; Santoriello, M.; Caroli, A.; Hartmann, R. W.; Sbardella, G. CYP19 (aromatase): exploring the scaffold flexibility for novel selective inhibitors Bioorg. Med. Chem. 2008, 16, 8349-8358
17. Lucas, S.; Heim, R.; Ries, C.; Schewe, K. E.; Birk, B.; Hartmann, R. W. In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1 H -quinolin-2-one derivatives J. Med. Chem. 2008, 51, 8077-8087
18. Lucas, S.; Heim, R.; Negri, M.; Antes, I.; Ries, C.; Schewe, K. E.; Bisi, A.; Gobbi, S.; Hartmann, R. W. Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach J. Med. Chem. 2008, 51, 6138-6149
19. Heim, R.; Lucas, S.; Grombein, C. M.; Ries, C.; Schewe, K. E.; Negri, M.; Müller-Vieira, U.; Birk, B.; Hartmann, R. W. Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity J. Med. Chem. 2008, 51, 5064-5074
20. Ulmschneider, S.; Müller-Vieira, U.; Klein, C. D.; Antes, I.; Lengauer, T.; Hartmann, R. W. Synthesis and evaluation of (pyridylmethylene) tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase J. Med. Chem. 2005, 48, 1563-1575
21. Ulmschneider, S.; Müller-Vieira, U.; Mitrenga, M.; Hartmann, R. W.; Oberwinkler-Marchais, S.; Klein, C. D.; Bureik, M.; Bernhardt, R.; Antes, I.; Lengauer, T. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethylene indanes: potent inhibitors of aldosterone synthase J. Med. Chem. 2005, 48, 1796-1805 (Pubitemid 40396312)
22. l7,20-lyase): potential agents for the treatment of prostatic cancer J. Med. Chem. 1995, 38, 2463-2471
23. Attard, G.; Reid, A. H. M.; Yap, T. A.; Raynaud, F.; Dowsett, M.; Settatree, S.; Barrett, M.; Parker, C.; Martins, V.; Folkerd, E.; Clark, J.; Cooper, C. S.; Kaye, S. B.; Dearnaley, D.; Lee, G.; de Bono, J. S. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven J. Clin. Oncol. 2008, 26, 4563-4571
24. 17-20-lyase) and 5α-reductase types 1 and 2 J. Med. Chem. 2000, 43, 4266-4277
25. Njar, V. C. O.; Kato, K.; Nnane, I. P.; Grigoryev, D. N.; Long, B. J.; Brodie, A. M. H. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17α-hydroxylase-C17,20-lyase (P450 17α): potential agents for the treatment of prostate cancer J. Med. Chem. 1998, 41, 902-912
26. Wächter, G. A.; Hartmann, R. W.; Sergejew, T.; Grün, G. L.; Ledergerber, D. Tetrahydronaphthalenes: influence of heterocyclic substituents on inhibition of steroidogenic enzymes P450 arom and P450 17 J. Med. Chem. 1996, 39, 834-841
27. Hutschenreuter, T. U.; Ehmer, P. E.; Hartmann, R. W. Synthesis of hydroxy derivatives of highly potent non-steroidal CYP 17 inhibitors as potential metabolites and evaluation of their activity by a noncellular assay using recombinant human enzyme J. Enzyme Inhib. Med. Chem. 2004, 19, 17-32
28. Jagusch, C.; Negri, M.; Hille, U. E.; Hu, Q.; Bartels, M.; Jahn-Hoffmann, K.; Pinto-Bazurco Mendieta, M. A. E.; Rodenwaldt, B.; Müller-Vieira, U.; Schmidt, D.; Lauterbach, T.; Recanatini, M.; Cavalli, A.; Hartmann, R. W. Synthesis, biological evaluation and molecular modeling studies of methyleneimidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17,20-lyase (CYP17). Part I: heterocyclic modifications of the core structure Bioorg. Med. Chem. 2008, 16, 1992-2010
29. Hu, Q.; Negri, M.; Jahn-Hoffmann, K.; Zhuang, Y.; Olgen, S.; Bartels, M.; Müller-Vieira, U.; Lauterbach, T.; Hartmann, R. W. Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17,20-lyase (CYP17). Part II: Core rigidification and influence of substituents at the methylene bridge Bioorg. Med. Chem. 2008, 16, 7715-7727
30. Leroux, F.; Hutschenreuter, T. U.; Charriere, C.; Scopelliti, R.; Hartmann, R. W. N -(4-Biphenylmethyl)imidazoles as potential therapeutics for the treatment of prostate cancer: metabolic robustness due to fluorine substitution? Helv. Chim. Acta 2003, 86, 2671-2686
31. Hille, U. E.; Hu, Q.; Vock, C.; Negri, M.; Bartels, M.; Müller-Vieira, U.; Lauterbach, T.; Hartmann, R. W. Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modeling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls Eur. J. Med. Chem. 2009, 44, 2765-2775
32. Hu, Q.; Negri, M.; Olgen, S.; Hartmann, R. W. The role of fluorine substitution in biphenyl methylene imidazole type CYP17 inhibitors for the treatment of prostate carcinoma. ChemMedChem 2010, DOI: 10.1002/cmdc.201000065.
33. Hu, Q.; Jagusch, C.; Hille, U. E.; Haupenthal, J.; Hartmann, R. W. Replacement of imidazolyl by pyridyl in biphenyl methylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer. J. Med. Chem., submitted.
34. Ehmer, P. B.; Jose, J.; Hartmann, R. W. Development of a simple and rapid assay for the evaluation of inhibitors of human 17alpha-hydroxylase-C(17,20)- lyase (P450cl7) by coexpression of P450cl7 with NADPH-cytochrome-P450-reductase in Escherichia coli J. Steroid Biochem. Mol. Biol. 2000, 75, 57-63
35. White, P. C.; Curnow, K. M.; Pascoe, L. Disorders of steroid 11β-hydroxylase isozymes Endocr. Rev. 1994, 15, 421-38
36. Booth, E. A.; Marchesi, M.; Kilbourne, E. J.; Lucchesi, B. R. 17Beta-estradiol as a receptor-mediated cardioprotective agent J. Pharmacol. Exp. Ther. 2003, 307, 395-401
37. Vandenput, L.; Ohlsson, C. Estrogens as regulators of bone health in men Nat. Rev. Endocrinol. 2009, 5, 437-443